loading
Novabay Pharmaceuticals Inc stock is traded at $1.4791, with a volume of 140.98K. It is up +0.68% in the last 24 hours and down -60.89% over the past month. NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$1.46
Open:
$1.46
24h Volume:
140.98K
Relative Volume:
0.32
Market Cap:
$38.40M
Revenue:
$4.75M
Net Income/Loss:
$-7.83M
P/E Ratio:
6.7942
EPS:
0.2177
Net Cash Flow:
$-7.24M
1W Performance:
-3.92%
1M Performance:
-60.89%
6M Performance:
-92.12%
1Y Performance:
-49.35%
1-Day Range:
Value
$1.41
$1.51
1-Week Range:
Value
$1.29
$1.699
52-Week Range:
Value
$1.29
$99.75

Novabay Pharmaceuticals Inc Stock (NBY) Company Profile

Name
Name
Novabay Pharmaceuticals Inc
Name
Phone
510-899-8800
Name
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Name
Employee
86
Name
Twitter
@NovaBayPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NBY's Discussions on Twitter

Compare NBY vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NBY
Novabay Pharmaceuticals Inc
1.47 38.14M 4.75M -7.83M -7.24M 0.2177
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.70 121.40B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
762.45 83.25B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
721.77 46.39B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.03 43.41B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.37 33.09B 5.36B 287.73M 924.18M 2.5229

Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-18-19 Initiated Ladenburg Thalmann Buy
Jul-06-18 Reiterated H.C. Wainwright Buy
Nov-15-17 Reiterated Laidlaw Buy
Jun-05-17 Initiated ROTH Capital Buy
Mar-27-17 Initiated Laidlaw Buy
Feb-06-17 Initiated Rodman & Renshaw Buy
Mar-07-16 Downgrade Maxim Group Buy → Hold
Dec-14-15 Reiterated Maxim Group Buy
Apr-30-15 Resumed Maxim Group Buy
Mar-06-13 Initiated Ascendiant Capital Markets Strong Buy
Jan-03-08 Initiated Dawson James Speculative Buy
View All

Novabay Pharmaceuticals Inc Stock (NBY) Latest News

pulisher
Mar 04, 2026

NBY Earnings History & Surprises | EPS & Revenue Results | NOVABAY PHARMACEUTICALS INC (NYSEARCA:NBY) - ChartMill

Mar 04, 2026
pulisher
Mar 03, 2026

Breakouts Watch: What are the risks of holding NovaBay Pharmaceuticals IncPortfolio Growth Summary & Weekly Market Pulse Updates - baoquankhu1.vn

Mar 03, 2026
pulisher
Mar 02, 2026

Gross margin % of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Mar 02, 2026
pulisher
Feb 28, 2026

NBY SEC FilingsNovabay Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 28, 2026
pulisher
Feb 26, 2026

Net current asset value per share of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

NovaBay Pharmaceuticals, Inc. Earnings and Revenue – GETTEX:B9P1 - TradingView

Feb 26, 2026
pulisher
Feb 25, 2026

Cash per share of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Diluted net income available to common stockholders of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Debt to assets ratio of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Tangible book value per share of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Net current asset value per share of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Enterprise value to EBITDA ratio of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Free cash flow per share of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Operating income of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Price to cash flow ratio of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Diluted shares outstanding of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Total revenue of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Free cash flow of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Enterprise value of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Operating expenses (excl. COGS) of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Number of employees of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Gross margin % of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Operating margin % of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Return on invested capital % of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Diluted earnings per share (diluted EPS) of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

EBITDA of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Free cash flow per share of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

EBITDA per share of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Total liabilities of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Debt to equity ratio of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Cash from operating activities of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Long term debt to total equity ratio of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

NovaBay Pharmaceuticals, Inc. Earnings and Revenue – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

EBIT of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Operating income of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Average basic shares outstanding of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Total operating expenses of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Net debt of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Total liabilities & shareholders' equities of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Cost of goods sold of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Total equity of NovaBay Pharmaceuticals, Inc. – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Quick ratio of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

NovaBay Pharmaceuticals, Inc. Cash Flow – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

NovaBay Pharmaceuticals, Inc. Income Statement – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Total debt per share of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Net margin % of NovaBay Pharmaceuticals, Inc. – GETTEX:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

NovaBay Pharmaceuticals, Inc. Balance Sheet – MUN:B9P1 - TradingView

Feb 25, 2026
pulisher
Feb 24, 2026

Diluted earnings per share (diluted EPS) of NovaBay Pharmaceuticals, Inc. – FWB:B9P1 - TradingView

Feb 24, 2026
pulisher
Feb 24, 2026

NovaBay Pharmaceuticals, Inc. Financial Statements – MUN:B9P1 - TradingView

Feb 24, 2026
pulisher
Feb 24, 2026

NovaBay Pharmaceuticals, Inc. Dividends – MUN:B9P1 - TradingView

Feb 24, 2026

Novabay Pharmaceuticals Inc Stock (NBY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$45.53
price down icon 4.07%
$53.28
price down icon 7.69%
$29.74
price up icon 0.71%
$103.05
price down icon 0.96%
$143.26
price down icon 4.74%
biotechnology ONC
$290.72
price down icon 2.57%
Cap:     |  Volume (24h):